The prescribing information for metformin ER tablets describes metformin as a biguanidine antihyperglycemic agent and states the tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The label describes how it works, while review abstracts describe proposed mechanisms in cautious terms. This guide keeps three things apart: what the label states, what review abstracts propose, and what is off-label.
What metformin and an extended-release tablet are
The prescribing information for metformin ER tablets describes metformin as a "biguanidine antihyperglycemic agent" in the form of monohydrochloride salt. The same label lists a 500 mg extended-release tablet, described as a biconvex-shaped, white-colored, film-coated tablet imprinted with 0019 and 500 on one side. The patient information leaflet in a second metformin ER label says its tablets are not for people with type 1 diabetes.
What the label says it is for
The label's indication statement reads: indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The NIDDK page on diabetes medicines states that most people with type 2 diabetes start with metformin pills. The Drugs@FDA approval history for Glucophage XR (metformin hydrochloride) extended-release tablets lists an original approval dated 10/13/2000, classified as a new dosage form (Type 3).
How the label says it works
The mechanism section of the prescribing information says metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. The label also states that with metformin therapy insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may decrease. In plainer words, NIDDK says metformin helps your liver make less glucose and helps your body use insulin better.
What review abstracts say about proposed mechanisms
The label's mechanism statements above are regulatory text. The entries below come from review abstracts, which summarize published work rather than report a new trial. They use cautious words such as "may", "might" and "proposed", and they put the emphasis in different places.
| Question | What the source says |
|---|---|
| Is activation of the energy-sensor AMPK the whole story? | A review abstract says metformin-induced activation of AMPK is well documented but may not account for all actions of the drug. |
| Do lab findings match clinical concentrations? | A review abstract says complex I inhibition leading to AMPK activation has only been observed at supra-pharmacological (>1 mM) metformin concentrations, which do not occur in the clinical setting. |
| What sits at the centre of the proposed mechanism? | A review abstract says the discovery that metformin inhibits mitochondrial respiratory chain complex 1 placed energy metabolism and AMPK activation at the centre of its proposed mechanism of action. |
| Are there effects that do not involve AMPK? | A review abstract says key AMPK-independent effects include mitochondrial actions that are still thought to be the primary site of action of metformin. |
| What about tumourigenesis? | A review abstract says metformin might influence tumourigenesis, indirectly through systemic reduction of insulin levels and directly via the induction of energetic stress, but that these effects require further investigation. |
Other uses are off-label
The FDA page on unapproved ("off label") use of approved drugs is about using an approved drug for a use that is not approved. A use outside the indication statement quoted earlier is such a use.
The same page says healthcare providers generally may prescribe an approved drug for an unapproved use when they judge that it is medically appropriate for their patient. It also says FDA has not determined that the drug is safe and effective for the unapproved use. The patient information leaflet in the metformin ER label says medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet.
What this does not tell you
This guide reports label statements and review abstracts. It does not show that any proposed mechanism explains an effect in a particular person, and it does not say what metformin does for any purpose beyond the label's indication. The abstracts above are summaries of reviews, so they describe ideas under study rather than settled findings. The abstract on tumourigenesis says its effects require further investigation, and this guide makes no claim about them. It does not cover dosing, side effects or kidney limits. Whether metformin is appropriate for a specific person is a decision for a licensed provider.